Written by: Eman N. Chaudhri, MD, Department of Urology, University of California, Irvine, @EmanChaudhri on Twitter during the American Urological Association's 2025 Annual Meeting, between April 26 – ...

Dr. Huang concluded this presentation discussing results of a phase II study of tislelizumab as neoadjuvant treatment for cisplatin-ineligible high-risk upper tract urothelial carcinoma with the ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the Society of Urologic Oncology (SUO) Session. Dr. Bernard ...

Dr. Kazuyuki Numakura presented a study of primary resistance to nivolumab + ipilimumab therapy affecting second-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients. Long-term ...

Of the 422 patients, 198 (47%) experienced a recurrence following surgery. There was an almost even split between early (34%), mid (33%), and late recurrences (32%). Time to recurrence was associated ...

Each patient underwent sequential laser activation in three commonly used modes: fragmentation (low power), dusting (moderate power), and pop-dusting (high power), with temperatures recorded ...

(UroToday.com) The American Urological Association (AUA) 2025 Annual Meeting, held in Las Vegas, NV, was host to an advanced prostate cancer podium session. Dr. Alejandro Sanchez presented the results ...

The SOPHIA study retrospectively investigated the first-in-man safety and efficacy in 6 patients with stress urinary incontinence who received the UroActive TM device. Results from the primary ...

Data was drawn from the Urology Residency Match (SAU Match) survey administered annually by the AUA. Participation remained strong across the three years, with 440, 428, and 387 applicants responding ...

The positive predictive value (PPV) for Bladder EpiCheck was 67.4%, with a negative predictive value (NPV) for both overall and HG disease of 99.6%. WLC demonstrated a PPV of 74%, an NPV of 96.3%, and ...

Minh Nguyen, MS2, from the Brody School of Medicine at East Carolina University, presented findings on the evolving trends in pelvic lymph node dissection (PLND) during radical prostatectomy. Her ...

Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in ...